The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
David R. Gandara
No relevant relationships to disclose
Sandrine Hiret
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Fabrice Barlesi
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Jeannick Madelaine
No relevant relationships to disclose
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Karen L. Reckamp
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI
Christine Audebert
No relevant relationships to disclose
Byoung Chul Cho
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Fadi S. Braiteh
Consultant or Advisory Role - Agendia; Spectrum Pharmaceuticals
Honoraria - Amgen; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Dendreon; Genomic Health; INSYS; Myriad Genetics; Novartis; Pfizer
Research Funding - Bayer; Foundation Medicine; Genentech; Genomic Health; GlaxoSmithKline; Lilly; Merrimack; Myriad Genetics; Novartis; Onyx; Pfizer
Robert M. Jotte
No relevant relationships to disclose
Yuehui Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Daniel J. Schramek
Employment or Leadership Position - GlaxoSmithKline
Alexandra M. Piepszak
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Olivia S. Gardner
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vijay Gopal Reddy Peddareddigari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Natasha B. Leighl
No relevant relationships to disclose